ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

VNDA vs UNH // EV/EBITDA & P/E VALUATION

Vanda Pharmaceuticals Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: VNDA 1 — UNH 8
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VNDA VS. UNH) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC VNDA UNH SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 88.57% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 11.47% -46.47 UNH /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 16.4x — TIE /valuation <GO>
Free Cash Flow Yield — 6.48% — TIE /fcf-yield <GO>
Operating Margin -60.00% 4.82% -64.82 UNH /operating-margins <GO>
Net Profit Margin -60.00% 3.14% -63.14 UNH /net-margins <GO>
Revenue Growth (YoY) 8.70% 6.46% +2.24 VNDA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 2.28% -2.28 UNH /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 3.12 -2.92 UNH /balance-sheet <GO>
Piotroski F-Score Quality 3/9 7/9 -4.00 UNH /piotroski-score <GO>
Options Implied Move & Put/Call Skew — 6.74% — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 26.7 59.2 -32.53 UNH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — 0.33 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 17.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $244.9M $368.83B -$368.59B UNH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR VNDA REV UNH REV VNDA GROSS % UNH GROSS % VNDA FCF UNH FCF
FY 2025 $216.1M $447.57B — 88.7% -$110.4M $16.07B
FY 2024 $198.8M $400.28B — 88.3% -$16.2M $20.70B
FY 2023 $192.6M $371.62B — 89.6% $12.8M $25.68B
FY 2022 — $324.16B — 89.6% — $23.40B
FY 2021 — $287.60B — 89.2% — $19.89B
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VNDA // BETA —
UNH // BETA 0.33